HIV & AIDS

Gilead, Merck team up to develop long-acting HIV drug

American pharmaceutical companies Gilead and Merck announced Monday they have partnered to develop a new HIV therapy that could see daily medications replaced by a treatment that can be taken at longer intervals.

HIV & AIDS

Among Blacks, late-stage HIV diagnosis varies by rurality

(HealthDay)—The percentage of Black people with late-stage HIV diagnosis varies according to population area of residence and is higher in rural than urban and metropolitan areas, according to research published in the ...

Cardiology

Radiomics shows cocaine fuels coronary artery disease risk

Radiomics—the extraction of very detailed quantitative features from medical images—provides a refined understanding of how cocaine use and other risk factors affect the course of coronary artery disease, according to ...

HIV & AIDS

Human immune cells have natural alarm system against HIV

Treatment for HIV has improved tremendously over the past 30 years; once a death sentence, the disease is now a manageable lifelong condition in many parts of the world. Life expectancy is about the same as that of individuals ...

page 22 from 40